CBFβ Inhibitor

Research use only, not for human use.

CBFβ Inhibitor is a cell-permeable CBFβ inhibitor and inhibits its association with Runx1.

CBFβ Inhibitor is a cell-permeable CBFβ inhibitor and inhibits its association with Runx1.(In Vitro):The ELISA results have shown that CBFβ Inhibitor is very effective in inhibiting the CBFβ-Runx1 interaction (IC50: 3.2 μM). In the leukemia cell line ME-1 expressing CBFβ-SMMHC, CBFβ Inhibitor reduced cell proliferation dose-dependently. Treatment with CBFβ Inhibitor for 3 days showed an increase in apoptotic cells. Treatment with CBFβ Inhibitor for 14 days individually or with all-trans-retinoic acid (ATRA) resulted in cells with greater variation in size and shape, lower nuclear-to-cytoplasmic ratio, increased folding, and lobation of nuclei, and more clumped chromatin. All of these morphology changes are consistent with differentiation to more mature forms. CBFβ Inhibitor at 50 μM increased proliferation of Hep-G2 cells. CBFβ treatment with Inhibitor resulted in a statistically significant reduction in Runx1 bound to DNA .

——

——

5-Ethyl-4-(4-methoxy-phenyl)-thiazol-2-ylamine

Cell Cycle/DNA Damage

DNA/RNA Synthesis

Cleavable

——

——

493028-20-9

234.32

C12H14N2OS

>98% (HPLC)

——

CCc1sc(N)nc1-c1ccc(OC)cc1

——

(-20℃)

With Ice Pack

≥ 2 years